Danaher Corporation (DHR) stock analysis and fair value

DHR · NYSE · Healthcare

224,74 US$

▲ +0,14%

Cerne score

46out of 100

Weak

  • Quality83
  • Growth25
  • Financial strength77
  • Valuation15
  • Dividends50

In 30 seconds

The business. Healthcare. Sells 24,6 B US$ a year, keeps 15% as profit and sales grow 2,0% a year (last 5 years).

The price. More expensive than usual: you pay 45x earnings, when its normal is 38x.

Strength. Passes 3 of 8 quality checks, but debt weighs: 3,8 years of profit.

DHR fair value

Work out what the stock is worth with your own growth, margin and return assumptions. Free during launch.

See the fair value

Danaher Corporation key numbers

Market cap
158 B US$
P/E (price ÷ earnings)
44,6
Dividend yield
0,55%
Revenue growth
4,3%
a year, over 9 years
Profit margin
14,7%
Quality checks
3/8

Fiscal 2025 financials, as filed with the SEC.

What analysts say

Buy

22 of 26 analysts recommend buying. Average price target: 231,82 US$.

About Danaher Corporation

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.

See everything about DHR on Cerne

  • Fair value with your own assumptions
  • Every analyst and price target
  • 10 years of financials in simple charts
  • Dividends, earnings and ratios vs. the sector
Request access